A Single Arm, Open-Label Pilot Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL) Stage IB to IV
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Venetoclax (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Adverse reactions
Most Recent Events
- 22 Jun 2021 Status changed from recruiting to completed.
- 13 Jan 2021 Planned End Date changed from 31 Aug 2021 to 31 Mar 2022.
- 13 Jan 2021 Planned primary completion date changed from 28 Feb 2021 to 31 Dec 2021.